←Back to Expert Scholars
Translational Medicine / 转化医学Breast Cancer, Elacestrant ESR1
Aditya Bardia
MD, MPH
🏢UCLA Jonsson Comprehensive Cancer Center🌐USA
Director, Breast Cancer Research Program
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Aditya Bardia led the EMERALD trial establishing elacestrant as an oral SERD option for ESR1-mutant HR-positive metastatic breast cancer after CDK4/6 progression. He also led TROPiCS-02 of sacituzumab govitecan. His work focuses on sequencing strategies post-CDK4/6.
Share:
🧪Research Fields 研究领域
EMERALD trial
elacestrant oral SERD
TROPiCS-02 sacituzumab
ctDNA biomarkers
HR-positive resistance
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Aditya Bardia 的研究动态
Follow Aditya Bardia's research updates
留下邮箱，当我们发布与 Aditya Bardia（UCLA Jonsson Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment